Inozyme Pharma Inc (NASDAQ: INZY) is -48.74% lower on its value in year-to-date trading and has touched a low of $1.24 and a high of $7.80 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The INZY stock was last observed hovering at around $1.52 in the last trading session, with the day’s loss setting it -0.1%.
Currently trading at $1.42, the stock is -27.23% and -42.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.89 million and changing -6.58% at the moment leaves the stock -66.92% off its SMA200. INZY registered -69.85% loss for a year compared to 6-month loss of -75.26%. The firm has a 50-day simple moving average (SMA 50) of $2.5332 and a 200-day simple moving average (SMA200) of $4.311.
The stock witnessed a -53.44% gain in the last 1 month and extending the period to 3 months gives it a -70.35%, and is 9.23% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.61% over the week and 11.96% over the month.
Inozyme Pharma Inc (INZY) has around 59 employees, a market worth around $91.22M and $0.00M in sales. Distance from 52-week low is 14.98% and -81.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-77.18%).
The EPS is expected to shrink by -16.59% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
129.0 institutions hold shares in Inozyme Pharma Inc (INZY), with institutional investors hold 99.42% of the company’s shares. The shares outstanding are 64.18M, and float is at 43.99M with Short Float at 8.76%. Institutions hold 98.92% of the Float.
The top institutional shareholder in the company is ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares valued at $25.55 million. The investor’s holdings represent 9.2742 of the INZY Shares outstanding. As of 2024-06-30, the second largest holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC with 4.49 million shares valued at $20.05 million to account for 7.2765 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 4.28 million shares representing 6.9292 and valued at over $19.09 million, while EVENTIDE ASSET MANAGEMENT, LLC holds 6.3721 of the shares totaling 3.94 million with a market value of $17.56 million.
Inozyme Pharma Inc (INZY) Insider Activity
The most recent transaction is an insider sale by Treco Douglas A, the company’s CEO. SEC filings show that Treco Douglas A sold 7,523 shares of the company’s common stock on Apr 02 ’24 at a price of $6.94 per share for a total of $52210.0. Following the sale, the insider now owns 20665.0 shares.
